These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20338781)

  • 1. Assays and reference materials for current and future applications of heparins.
    Mulloy B; Hogwood J; Gray E
    Biologicals; 2010 Jul; 38(4):459-66. PubMed ID: 20338781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of biologically active heparan sulfate and heparin using an enzyme-based approach.
    Peterson S; Frick A; Liu J
    Nat Prod Rep; 2009 May; 26(5):610-27. PubMed ID: 19387498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic heparin and heparan sulfate: probes in defining biological functions.
    Tsai CT; Zulueta MML; Hung SC
    Curr Opin Chem Biol; 2017 Oct; 40():152-159. PubMed ID: 29032302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and anticoagulation.
    Onishi A; St Ange K; Dordick JS; Linhardt RJ
    Front Biosci (Landmark Ed); 2016 Jun; 21(7):1372-92. PubMed ID: 27100512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin affin regulatory peptide modulates the endogenous anticoagulant activity of heparin and heparan sulphate mimetics.
    Mejdoubi-Charef N; Courty J; Sineriz F; Papy-Garcia D; Charef S
    Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):296-302. PubMed ID: 22672269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of heparin and heparan sulfate microarrays.
    Yin J; Seeberger PH
    Methods Enzymol; 2010; 478():197-218. PubMed ID: 20816481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical studies on sulfated lactobionic acid amides.
    Klauser RJ; Meinetsberger E; Raake W
    Semin Thromb Hemost; 1991; 17 Suppl 1():118-25. PubMed ID: 1648790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity.
    Linhardt RJ
    J Med Chem; 2003 Jun; 46(13):2551-64. PubMed ID: 12801218
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential of the molecular diversity of heparin and heparan sulfate for drug development.
    Fügedi P
    Mini Rev Med Chem; 2003 Nov; 3(7):659-67. PubMed ID: 14529507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production methods for heparosan, a precursor of heparin and heparan sulfate.
    Chavaroche AA; van den Broek LA; Eggink G
    Carbohydr Polym; 2013 Mar; 93(1):38-47. PubMed ID: 23465899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
    Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
    Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.
    Condac E; Strachan H; Gutierrez-Sanchez G; Brainard B; Giese C; Heiss C; Johnson D; Azadi P; Bergmann C; Orlando R; Esmon CT; Harenberg J; Moremen K; Wang L
    Glycobiology; 2012 Sep; 22(9):1183-92. PubMed ID: 22641771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbial heparin/heparan sulphate lyases: potential and applications.
    Tripathi CK; Banga J; Mishra V
    Appl Microbiol Biotechnol; 2012 Apr; 94(2):307-21. PubMed ID: 22391972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties.
    Avci FY; Karst NA; Linhardt RJ
    Curr Pharm Des; 2003; 9(28):2323-35. PubMed ID: 14529394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of unfractionated heparin: comparison of materials from the last 50 years.
    Mulloy B; Gray E; Barrowcliffe TW
    Thromb Haemost; 2000 Dec; 84(6):1052-6. PubMed ID: 11154113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A collaborative study of proposed European Pharmacopoeia reference preparations of low molecular mass heparin.
    Gray E; Heath AB; Mulloy B; Spieser JM; Barrowcliffe TW
    Thromb Haemost; 1995 Sep; 74(3):893-9. PubMed ID: 8571317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.